Literature DB >> 12679932

Effect of transforming growth factor beta and bone morphogenetic proteins on rat hepatic stellate cell proliferation and trans-differentiation.

Hong Shen1, Guo-Jiang Huang, Yue-Wen Gong.   

Abstract

AIM: To explore different roles of TGF-beta (transforming growth factor beta) and bone morphogenetic proteins (BMPs) in hepatic stellate cell proliferation and trans-differentiation.
METHODS: Hepatic stellate cells were isolated from male Sprague-Dawley rats. Sub-cultured hepatic stellate cells were employed for cell proliferation assay with WST-1 reagent and Western blot analysis with antibody against smooth muscle alpha actin (SMA).
RESULTS: The results indicated that TGF-beta1 significantly inhibited cell proliferation at concentration as low as 0.1 ng/ml, but both BMP-2 and BMP-4 did not affect cell proliferation at concentration as high as 10 ng/ml. The effect on hepatic stellate cell trans-differentiation was similar between TGF-beta1 and BMPs. However, BMPs was more potent at trans-differentiation of hepatic stellate cells than TGF-beta1. In addition, we observed that TGF-beta1 transient reduced the abundance of SMA in hepatic stellate cells.
CONCLUSION: TGF-beta may be more important in regulation of hepatic stellate cell proliferation while BMPs may be the major cytokines regulating hepatic stellate cell trans-differentiation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679932      PMCID: PMC4611450          DOI: 10.3748/wjg.v9.i4.784

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

1.  TGFbeta and BMP-2 activation of the OPN promoter: roles of smad- and hox-binding elements.

Authors:  T G Hullinger; Q Pan; H L Viswanathan; M J Somerman
Journal:  Exp Cell Res       Date:  2001-01-01       Impact factor: 3.905

Review 2.  Signaling of transforming growth factor-beta family members through Smad proteins.

Authors:  S Itoh; F Itoh; M J Goumans; P Ten Dijke
Journal:  Eur J Biochem       Date:  2000-12

Review 3.  Smad proteins and transforming growth factor-beta signaling.

Authors:  M Schiffer; G von Gersdorff; M Bitzer; K Susztak; E P Böttinger
Journal:  Kidney Int Suppl       Date:  2000-09       Impact factor: 10.545

Review 4.  Bone morphogenetic proteins in development.

Authors:  B L Hogan
Journal:  Curr Opin Genet Dev       Date:  1996-08       Impact factor: 5.578

Review 5.  Hepatic fibrogenesis.

Authors:  B H Davis; T F Kresina
Journal:  Clin Lab Med       Date:  1996-06       Impact factor: 1.935

6.  Isoforms and splice variant of transforming growth factor beta-binding protein in rat hepatic stellate cells.

Authors:  W Gong; S Roth; K Michel; A M Gressner
Journal:  Gastroenterology       Date:  1998-02       Impact factor: 22.682

Review 7.  Hepatic stellate cells.

Authors:  S L Friedman
Journal:  Prog Liver Dis       Date:  1996

8.  Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells.

Authors:  M Pinzani; L Gesualdo; G M Sabbah; H E Abboud
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

9.  Transforming growth factor beta signaling through Smad1 in human breast cancer cells.

Authors:  X Liu; J Yue; R S Frey; Q Zhu; K M Mulder
Journal:  Cancer Res       Date:  1998-10-15       Impact factor: 12.701

10.  Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP.

Authors:  Y Gong; L J Blok; J E Perry; J K Lindzey; D J Tindall
Journal:  Endocrinology       Date:  1995-05       Impact factor: 4.736

View more
  10 in total

1.  Bone morphogenetic protein-2 is a negative regulator of hepatocyte proliferation downregulated in the regenerating liver.

Authors:  Cui-Ping Xu; Wen-Min Ji; Gijs R van den Brink; Maikel P Peppelenbosch
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

Review 2.  Bone morphogenetic proteins and their antagonists: current and emerging clinical uses.

Authors:  Imran H A Ali; Derek P Brazil
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

3.  Transforming Growth Factors α and β Are Essential for Modeling Cholangiocarcinoma Desmoplasia and Progression in a Three-Dimensional Organotypic Culture Model.

Authors:  Miguel Á Manzanares; Akihiro Usui; Deanna J Campbell; Catherine I Dumur; Gabrielle T Maldonado; Michel Fausther; Jonathan A Dranoff; Alphonse E Sirica
Journal:  Am J Pathol       Date:  2017-03-15       Impact factor: 4.307

4.  Expression of Fc Fragment Receptors of Immunoglobulin G (FcγRs) in Rat Hepatic Stellate Cells.

Authors:  Hong Shen; Manna Zhang; Kelly Kaita; Gerald Y Minuk; Julia Rempel; Yuewen Gong
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

5.  Upregulation of bone morphogenetic protein 4 is associated with poor prognosis in patients with hepatocellular carcinoma.

Authors:  Xiaodong Guo; Lu Xiong; Lin Zou; Jingmin Zhao
Journal:  Pathol Oncol Res       Date:  2012-02-15       Impact factor: 3.201

6.  Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool.

Authors:  Carlos Ernesto Fernández-García; Stephania C Isaza; Esther Rey; Patricia Marañón; Rocío Gallego-Durán; Rocío Montero-Vallejo; Javier Rodríguez de Cía; Javier Ampuero; Manuel Romero-Gómez; Carmelo García-Monzón; Águeda González-Rodríguez
Journal:  Biomark Res       Date:  2022-05-25

7.  Kangxian ruangan keli inhibits hepatic stellate cell proliferation mediated by PDGF.

Authors:  Ling Yang; Chi-Zhi Zhang; Qing-Jing Zhu
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

8.  Down-regulation of transforming growth factor beta 1/activin receptor-like kinase 1 pathway gene expression by herbal compound 861 is related to deactivation of LX-2 cells.

Authors:  Li Li; Xin-Yan Zhao; Bao-En Wang
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

9.  Expression of subtypes of somatostatin receptors in hepatic stellate cells.

Authors:  Sheng-Han Song; Xi-Sheng Leng; Tao Li; Zhi-Zhong Qin; Ji-Run Peng; Li Zhao; Yu-Hua Wei; Xin Yu
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

10.  Synergy of Phospholipid-Drug Formulations Significantly Deactivates Profibrogenic Human Hepatic Stellate Cells.

Authors:  Gina Valentino; Cristina Zivko; Florian Weber; Lorine Brülisauer; Paola Luciani
Journal:  Pharmaceutics       Date:  2019-12-12       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.